AstraZeneca Takes 12% Stake in Summit Therapeutics With $2 Billion Investment and Ivonescimab Combo Pact

SentiSense · Published · Updated

AstraZeneca agreed to invest $2 billion in Summit Therapeutics through convertible preferred stock, giving it rights to about 12% of Summit's common s...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis